Table 1.
Demographic and baseline features of the included patients.
| Total | ||
| n | 139 | |
| Gender, n (%) | ||
| M | 82 | (59%) |
| F | 57 | (41%) |
| Age at onset of thrombocytopenia, years | ||
| Median (range) | 4 (0–18) | |
| Baseline platelet count, ×109/L | ||
| Median (range) | 82 (2–147) | |
| Familiar history of thrombocytopenia, n (%) | ||
| Yes | 90 | (65%) |
| No | 49 | (35%) |
| Bleeding score (Buchanan and Adix bleeding score) | ||
| Median (range) | 0 (0–4) | |
| Therapies, n (%) | ||
| Yes | 46 | (33%) |
| Intravenous immunoglobulin | 15 | (32%) |
| Platelet transfusion | 12 | (26%) |
| Tranexamic acid | 12 | (26%) |
| Corticosteroids | 9 | (19%) |
| Ferrous sulfate | 6 | (13%) |
| Red blood cell transfusions | 5 | (11%) |
| thrombopoietin receptor agonists | 5 | (11%) |
| Folic acid | 2 | (4%) |
| Estrogen and progestin oral contraceptive | 2 | (4%) |
| Recombinant factor VIIa | 1 | (2%) |
| Antimicrobial prophylaxis | 1 | (2%) |
| Tegretol | 1 | (2%) |
| Dilatrend | 1 | (2%) |
| Erythropoietin | 1 | (2%) |
| Mycophenolate mofetil | 1 | (2%) |
| No | 93 | (67%) |